StreetAlpha.app
Home › Stocks › PMVP

PMV Pharmaceuticals, Inc. (PMVP)

$1.22
▲ +2.52%
LAST CLOSE · NOV 17

PMV Pharmaceuticals develops oral small molecule cancer drugs that target mutations in the p53 protein. It last closed at $1.22 on Nov 17, up 2.52% on the day.

AI Auto Pilots
Is PMVP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$88.5M
EPS (diluted)
−$1.56
Free cash flow
−$69.6M
Valuation
Market cap
$92.2M
75.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$20.0M
At Sep 30
Shareholder equity
$57.1M
Shares outstanding
75.5M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$57.8M−$57.8MFY2021FY2022: −$73.3M−$73.3MFY2022FY2023: −$69.0M−$69.0MFY2023FY2024: −$58.7M−$58.7MFY2024FY2025: −$77.7M−$77.7MFY2025

From PMVP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PMVP in the past 90 days, not enough for a consensus
Average 12-month target
$5.00
▲ 309.8% upside

Based on 1 analyst who set a price target on PMVP in the past 90 days. The average target is $5.00, with a high of $5.00 and a low of $5.00, compared with the last close of $1.22.

Low $5.00Avg $5.00High $5.00
Blue marker: last close $1.22
Highest target$5.00
Average target$5.00
Lowest target$5.00
Latest rating changes
HC Wainwright & Co.Reiterated
Sep 4Buy$5
Ladenburg ThalmannAssumed coverage
Jul 8Buy$3
DateFirmActionRatingPrice target
Sep 4HC Wainwright & Co.ReiteratedBuy$5
Jul 8Ladenburg ThalmannAssumed coverageBuy$3
Loading…

Technical Analysis

PMVP · as of the Nov 17 close · updated after every close
Turning down

The stock is 5% below its 20 day and 13% below its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 44). The nearest support is the swing low (Jul 6) at $1.20, and the nearest resistance the Pivot R1 at $1.28.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityNormal, 8.6%/day
Key levels
$1.9152 week high+56.6%
$1.3850 day average+13.1%
$1.32100 day average+8.2%
$1.31200 day average+7.4%
$1.29Swing high (Jun 2)+5.7%
$1.2820 day average+4.9%
$1.28Pivot R1+4.9%
$1.22Last close
$1.20Swing low (Jul 6)−1.6%
$1.17Pivot−4.1%
$1.12Pivot S1−8.2%
$1.0252 week low−16.4%
Indicators
RSI (14)44.43Middle of its rangeNeutral
MACD-0.04Below its signal lineBearish
Stochastic28.5Middle of its rangeNeutral
ADX (14)21.2Weak trend
Williams %R-59.5Oversold below −80, overbought above −20Neutral
CCI (20)-128.4Oversold below −100, overbought above 100Oversold
Rate of change−11.6%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PMVP

What happened before

See how PMVP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PMVP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PMVP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PMVP in the last 90 days.

Loading…

See today’s whale options flow across the market →

PMVP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲31 buying vs 21 selling
  • ▲Held by funds +29.0 pts
  • ▲Funds holding +1
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6564+1.6%
In funds' top 10220.0%
Held by funds74.8%45.8%+29.0 pts
New / increased9 / 224 / 15+63.2%
Reduced / sold out13 / 821 / 9−30.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PMVP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMVP is in one of them and how their past PMVP trades turned out.

PMVP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PMVP in an article yet. Here's the latest on the wider market.

About PMV Pharmaceuticals

PMV Pharmaceuticals is a cancer drug developer based in Princeton, New Jersey. It develops oral small molecule medicines that aim to restore normal function to mutant p53, a protein that helps stop cancer growth when it works properly. Its lead product candidate, rezatapopt, targets a specific p53 mutation found in several solid tumors, including some ovarian, lung and colorectal cancers. The company's therapies are intended for cancer patients whose tumors carry these mutations.

Headquarters
Princeton, NJ